B. Sierra-Rodero

发表

Role of immunotherapy in stage IIIA non-small cell lung cancer: a narrative review

V. Calvo, M. Provencio, B. Sierra-Rodero, 2020 .

Multiple ciliary localization signals control INPP5E ciliary targeting

Takanari Inoue, F. Garcia-Gonzalo, B. Sierra-Rodero, 2022, bioRxiv.

KRAS p.G12C mutation occurs in 1% of EGFR-mutated advanced non-small-cell lung cancer patients progressing on a first-line treatment with a tyrosine kinase inhibitor

M. Provencio, A. Romero, E. Sánchez-Herrero, 2021, ESMO open.

Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

N. Viñolas, B. Massuti, V. Calvo, 2022, Journal for ImmunoTherapy of Cancer.

Atezolizumab Plus Bevacizumab as First-line Treatment for Patients With Metastatic Nonsquamous Non–Small Cell Lung Cancer With High Tumor Mutation Burden

B. Massuti, V. Calvo, M. Provencio, 2022, JAMA oncology.

Pretreatment Tissue TCR Repertoire Evenness Is Associated with Complete Pathologic Response in Patients with NSCLC Receiving Neoadjuvant Chemoimmunotherapy

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical Cancer Research.

The Role of Metabolism in Tumor Immune Evasion: Novel Approaches to Improve Immunotherapy

M. Provencio, B. Sierra-Rodero, A. Cruz-Bermúdez, 2021, Biomedicines.

Clinical and molecular parameters associated to pneumonitis development in non-small-cell lung cancer patients receiving chemoimmunotherapy from NADIM trial

N. Viñolas, B. Massuti, M. Provencio, 2021, Journal for ImmunoTherapy of Cancer.

Blood biomarkers associated to complete pathological response on NSCLC patients treated with neoadjuvant chemoimmunotherapy included in NADIM clinical trial

I. Wistuba, N. Viñolas, B. Massuti, 2021, Clinical and translational medicine.